Moderators of fluoxetine treatment response for children and adolescents with comorbid depression and substance use disorders

被引:14
作者
Hirschtritt, Matthew E. [2 ]
Pagano, Maria E. [1 ,3 ]
Christian, Kelly M. [4 ]
McNamara, Nora K. [1 ]
Stansbrey, Robert J. [1 ]
Lingler, Jacqui [1 ]
Faber, Jon E. [1 ]
Demeter, Christine A. [1 ]
Bedoya, Denise [1 ]
Findling, Robert L. [1 ,3 ]
机构
[1] Univ Hosp Case Med Ctr, Cleveland, OH 44106 USA
[2] Case Western Reserve Univ, Cleveland Clin, Lerner Coll Med, Cleveland, OH 44195 USA
[3] Case Western Reserve Univ, Sch Med, Cleveland, OH 44106 USA
[4] Case Western Reserve Univ, Dept Psychol, Cleveland, OH 44106 USA
关键词
Depression; Dysthymia; Mediators; Moderators; Adolescents; Fluoxetine; Substance abuse; Alcohol; Marijuana; RANDOMIZED CONTROLLED-TRIAL; PLACEBO-CONTROLLED TRIAL; MAJOR DEPRESSION; DOUBLE-BLIND; ALCOHOL DEPENDENCE; SUICIDE ATTEMPTS; CLINICAL-TRIALS; RATING-SCALE; DRUG; METAANALYSIS;
D O I
10.1016/j.jsat.2011.09.010
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Our recent 8-week, randomized, placebo-controlled trial of fluoxetine in adolescents (ages 12-17 years) with comorbid depression and substance use disorder (SUD) did not detect a significant antidepressant treatment effect. The purpose of this secondary analysis was to explore moderators of the effect of fluoxetine in this sample. Static moderators measured at baseline were depression chronicity and hopelessness severity; time-varying moderators measured at baseline and weekly during the 8-week trial period were alcohol and marijuana use severity. Treatment effects on depression outcomes were examined among moderating subgroups in random effects regression models. Subjects assigned to fluoxetine treatment with chronic depression at baseline (p = .04) or no more than moderate alcohol use during the trial (p = .04) showed significantly greater decline in depression symptoms in comparison to placebo-assigned subgroups. The current analysis suggests that youth with chronic depression and no more than moderate alcohol consumption are likely to respond better to treatment with fluoxetine compared with placebo than youth with transient depression and heavy alcohol use. (C) 2012 Elsevier Inc. All rights reserved.
引用
收藏
页码:366 / 372
页数:7
相关论文
共 41 条
[21]   Sertraline for the prevention of relapse in detoxicated alcohol dependent patients with a comorbid depressive disorder: A randomized controlled trial [J].
Gual, A ;
Balcells, M ;
Torres, M ;
Madrigal, M ;
Diez, T ;
Serrano, L .
ALCOHOL AND ALCOHOLISM, 2003, 38 (06) :619-625
[22]  
Hedges L.V., 1994, The handbook of research synthesis, P285
[23]   COURSE OF MAJOR DEPRESSION IN NON-REFERRED ADOLESCENTS - A RETROSPECTIVE STUDY [J].
KELLER, MB ;
BEARDSLEE, W ;
LAVORI, PW ;
WUNDER, J ;
DRS, DL ;
SAMUELSON, H .
JOURNAL OF AFFECTIVE DISORDERS, 1988, 15 (03) :235-243
[24]   Psychiatric disorders and attempted suicide among adolescents with substance use disorders [J].
Kelly, TM ;
Cornelius, JR ;
Clark, DB .
DRUG AND ALCOHOL DEPENDENCE, 2004, 73 (01) :87-97
[25]   The epidemiology of major depressive disorder - Results from the National Comorbidity Survey Replication (NCS-R). [J].
Kessler, RC ;
Berglund, P ;
Demler, O ;
Jin, R ;
Koretz, D ;
Merikangas, KR ;
Rush, AJ ;
Walters, EE ;
Wang, PS .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 289 (23) :3095-3105
[26]   Initial severity and antidepressant benefits: A meta-analysis of data submitted to the food and drug administration [J].
Kirsch, Irving ;
Deacon, Brett J. ;
Huedo-Medina, Tania B. ;
Scoboria, Alan ;
Moore, Thomas J. ;
Johnson, Blair T. .
PLOS MEDICINE, 2008, 5 (02) :260-268
[27]   Mediators and moderators of treatment effects in randomized clinical trials [J].
Kraemer, HC ;
Wilson, GT ;
Fairburn, CG ;
Agras, WS .
ARCHIVES OF GENERAL PSYCHIATRY, 2002, 59 (10) :877-883
[28]   Sertraline treatment of co-occurring alcohol dependence and major depression [J].
Kranzler, HR ;
Mueller, T ;
Cornelius, J ;
Pettinati, HM ;
Moak, D ;
Martin, PR ;
Anthenelli, R ;
Brower, KJ ;
O'Malley, S ;
Mason, BJ ;
Hasin, D ;
Keller, M .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2006, 26 (01) :13-20
[29]   THE B-VALUE - A TOOL FOR MONITORING DATA [J].
LAN, KKG ;
WITTES, J .
BIOMETRICS, 1988, 44 (02) :579-585
[30]   DISCRETE SEQUENTIAL BOUNDARIES FOR CLINICAL-TRIALS [J].
LAN, KKG ;
DEMETS, DL .
BIOMETRIKA, 1983, 70 (03) :659-663